Skip to content

Nail changes in breast cancer patients receiving paclitaxel chemotherapy

Exploring paclitaxel inducednail changes in patients receiving weekly paclitaxel - A Clinical observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/062953
Enrollment
184
Registered
2024-02-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Dr. Ananth Pai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age = 18 years. Female patients Diagnosed with histologically verified, all malignancy breast and ovarian cancers for the first time. Planned for AC-Taxol protocol on weekly (Adriamycin and cyclophosphamide, followed by treatment with paclitaxel)

Exclusion criteria

Exclusion criteria: Any patients with previous dermatological or systematic disorders which affect nails. Serious nail changes that need interventional management such as acute paronychia and Onycholysis

Design outcomes

Primary

MeasureTime frame
1.Demographic characteristics, clinical presentations, histopathology reports, diagnostic results, and treatment details. 2.Evaluate the nails by using National Cancer Institute criteria (Common Terminology Criteria for Adverse Events, Version 4.0) by clinical examination.Timepoint: 0 weeks - baseline, 9th week and last chemotherapy

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr Ananth Pai

Kasturba Medical College and Hospital

ananth.pai@manipal.edu9880239139

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026